全文获取类型
| 收费全文 | 52644篇 |
| 免费 | 3778篇 |
| 国内免费 | 1110篇 |
专业分类
| 耳鼻咽喉 | 96篇 |
| 儿科学 | 1236篇 |
| 妇产科学 | 664篇 |
| 基础医学 | 2368篇 |
| 口腔科学 | 498篇 |
| 临床医学 | 7253篇 |
| 内科学 | 18013篇 |
| 皮肤病学 | 175篇 |
| 神经病学 | 661篇 |
| 特种医学 | 813篇 |
| 外国民族医学 | 1篇 |
| 外科学 | 6645篇 |
| 综合类 | 8469篇 |
| 现状与发展 | 3篇 |
| 一般理论 | 1篇 |
| 预防医学 | 2369篇 |
| 眼科学 | 81篇 |
| 药学 | 4977篇 |
| 47篇 | |
| 中国医学 | 2618篇 |
| 肿瘤学 | 544篇 |
出版年
| 2024年 | 38篇 |
| 2023年 | 886篇 |
| 2022年 | 1234篇 |
| 2021年 | 2118篇 |
| 2020年 | 2169篇 |
| 2019年 | 1947篇 |
| 2018年 | 1881篇 |
| 2017年 | 1711篇 |
| 2016年 | 1763篇 |
| 2015年 | 1819篇 |
| 2014年 | 3851篇 |
| 2013年 | 4082篇 |
| 2012年 | 2991篇 |
| 2011年 | 3518篇 |
| 2010年 | 2757篇 |
| 2009年 | 2764篇 |
| 2008年 | 2669篇 |
| 2007年 | 2682篇 |
| 2006年 | 2390篇 |
| 2005年 | 2218篇 |
| 2004年 | 1702篇 |
| 2003年 | 1432篇 |
| 2002年 | 1202篇 |
| 2001年 | 1126篇 |
| 2000年 | 812篇 |
| 1999年 | 708篇 |
| 1998年 | 563篇 |
| 1997年 | 519篇 |
| 1996年 | 483篇 |
| 1995年 | 443篇 |
| 1994年 | 437篇 |
| 1993年 | 313篇 |
| 1992年 | 280篇 |
| 1991年 | 275篇 |
| 1990年 | 239篇 |
| 1989年 | 239篇 |
| 1988年 | 223篇 |
| 1987年 | 162篇 |
| 1986年 | 138篇 |
| 1985年 | 141篇 |
| 1984年 | 115篇 |
| 1983年 | 65篇 |
| 1982年 | 77篇 |
| 1981年 | 70篇 |
| 1980年 | 57篇 |
| 1979年 | 58篇 |
| 1978年 | 44篇 |
| 1977年 | 31篇 |
| 1976年 | 35篇 |
| 1974年 | 15篇 |
排序方式： 共有10000条查询结果，搜索用时 109 毫秒
51.
52.
53.
54.
55.
56.
Javed Butler Mei Yang Massimiliano Alfonzo Manzi Gregory P. Hess Mahesh J. Patel Thomas Rhodes Michael M. Givertz 《Journal of the American College of Cardiology》2019,73(8):935-944
Background
Epidemiology of patients with worsening heart failure and reduced ejection fraction (HFrEF) in the real-world setting is not well described.Objectives
The purpose of this study was to describe incidence, clinical characteristics, treatment, and outcomes of patients with HFrEF who develop worsening heart failure (HF) in the real-world setting.Methods
Data on patients with incident HFrEF from the National Cardiovascular Data Registry PINNACLE were linked to pharmacy, private practitioner, and hospital claims databases. Incidence, clinical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist) and outcomes of patients with worsening HF, defined as ≥90 days of stable HF with subsequent worsening requiring intravenous diuretic agents, were assessed.Results
Of 11,064 HFrEF patients, 1,851 (17%) developed worsening HF on average 1.5 years following initial HF diagnosis. Patients who developed worsening HF were more likely to be African American, be octogenarians, and have higher comorbidity burden (p < 0.001). At the onset of worsening HF, 42.4% of patients were on monotherapy, 43.4% were on dual therapy, and 14.1% were on triple therapy. A total of 48%, 61%, and 98% of patients were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist, respectively. The 2-year mortality rate was 22.5%, and 56% of patients were rehospitalized within 30 days of the worsening HF event.Conclusions
In the real-world setting, 1 in 6 patients with HFrEF develop worsening HF within 18 months of HF diagnosis. These patients have a high risk for 2-year mortality and recurrent HF hospitalizations. The use of standard-of-care therapies both before and after the onset of worsening HF is low. With high unmet medical need, patients with worsening HF require novel treatment strategies as well as greater optimization of existing guideline-directed therapy. 相似文献57.
58.
59.
60.
Marco Giuseppe Del Buono Ross Arena Barry A. Borlaug Salvatore Carbone Justin M. Canada Danielle L. Kirkman Ryan Garten Paula Rodriguez-Miguelez Marco Guazzi Carl J. Lavie Antonio Abbate 《Journal of the American College of Cardiology》2019,73(17):2209-2225
Exercise intolerance is the cardinal symptom of heart failure (HF) and is of crucial relevance, because it is associated with a poor quality of life and increased mortality. While impaired cardiac reserve is considered to be central in HF, reduced exercise and functional capacity are the result of key patient characteristics and multisystem dysfunction, including aging, impaired pulmonary reserve, as well as peripheral and respiratory skeletal muscle dysfunction. We herein review the different modalities to quantify exercise intolerance, the pathophysiology of HF, and comorbid conditions as they lead to reductions in exercise and functional capacity, highlighting the fact that distinct causes may coexist and variably contribute to exercise intolerance in patients with HF. 相似文献